Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
VUEWAY should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The clinical benefit of VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of VUEWAY (gadopiclenol) at a dose of 0.05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
Avis rectifié en date du 26/11/2024
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
F6zRkRw90sraXeBt
